Why is Myriad Genetics stock surging today?

Myriad Genetics (MYGN) stock rose 21.4% in pre-market trading after announcing the sale of its Prenatal Health Testing Business to Labcorp for $210M in cash. The deal, expected to close by early 2027, includes four prenatal tests. CEO Sam Raha stated the transaction will boost revenue growth, profitability, and balance sheet strength, focusing on cancer care. The move follows a 16% year-over-year decline in prenatal revenue and a guidance cut.

Original reporting
Published Oct 20, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 1:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$MYGN
Bullish
high confidence
Mentioned
$MYGN
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MYGNBullishHigh
01

Why it matters

The cash proceeds improve liquidity and allow Myriad to concentrate on its oncology portfolio, which analysts view more favorably.

02

Market read

The deal is a material corporate action that drove a double‑digit pre‑market rally, offering a clear trading catalyst.

03

What to watch

Potential regulatory hurdles for the divestiture and integration risk for Labcorp could delay cash receipt.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Myriad Genetics has been under pressure from declining prenatal revenues and a full‑year guidance cut. The Labcorp transaction aims to monetize the underperforming unit.

Company-level read

Ticker impact

$MYGNBullishHigh confidence
Context

Myriad Genetics announced a definitive agreement to sell its Prenatal Health Testing Business to Labcorp for $210 million, triggering a 21.4% pre‑open price surge.

Expected impact

likely upward pressure as investors price in the cash infusion and strategic focus on oncology

Evidence & confidence

Deal size is material for a mid‑cap, the stock already jumped 21% on the news, and analysts have upgraded the rating.

Market effects

Strengthens the genetics/diagnostics sector by highlighting divestiture trends and focus on oncology pipelines.

U.S. biotech market may see modest uplift as a high‑profile divestiture is confirmed.

Limited to investors tracking M&A activity in the healthcare space.

Counterpoint

The sale could signal deeper weakness in Myriad's prenatal segment, suggesting the stock may be over‑reacting.

Key entities

  • Myriad Genetics

    US‑listed genetics testing firm (ticker MYGN).

  • Labcorp

    US‑listed clinical laboratory services provider (ticker LH).

Related articles

$MYGNHighAI 8/10

Myriad Genetics (MYGN) Q3 2026 Earnings Call Transcript

Myriad Genetics (MYGN) reported Q3 2026 revenue of $202.7M, with 4% volume growth in Cancer Care and 3% in Mental Health, offset by an 11% decline in Prenatal Health. The company announced the sale of its Prenatal Health business to Labcorp for $210M. Gross margin improved to 67.9%, and adjusted EBITDA and EPS showed sequential improvements. MYGN raised its 2026 revenue guidance to $780M-$790M, citing growth in Cancer Care and Mental Health tests.